Consort Partners’ Post

We are presenting new data at #ASGCT2024 demonstrating how we leverage our unique ML-driven platform to optimize sequences and modifications of engineered #tRNA that significantly improve in vivo activity. We will also be at TIDES USA discussing our strategies to synthesize chemically modified tRNAs focusing on stability, purity, and scale. ASGCT 27th Annual Meeting 📃Alltrna’s Head of Computational and Molecular Biology Stephen Eichhorn will present a poster on May 9th titled, “tRNA Therapeutics to Treat Stop Codon Disease.” TIDES USA 2024 🎤 Alltrna’s CTO William Kiesman will give a talk on May 17th to explore “Manufacturing Strategies for Chemically Modified tRNAs.” 📊 We will also have two posters in the exhibit hall throughout the #TIDESUSA event. “Building 3-D homology models to support tRNA structure-based drug design” will be presented by Audrey Hughes “Quantification of Tissue Delivery for tRNA Therapeutics in LNP Formulations” will be presented by W. George Lai. See this press release for details of all the presentations: https://lnkd.in/gDBAGJWU #AI #machinelearning #RNA #tRNAmedicines #tRNAbiology #geneticmedicines #programmablemedicines #drugdiscovery #drugmanufacturing #drugdelivery #StopCodonDisease

HuidaGene Therapeutics will present eleven research results, including one oral and ten poster presentations, at the European Society of Gene and Cell Therapy 31st Annual Congress (#ESGCT2024 ) from 22-25 October, in Rome. These presentations showcase the latest preclinical and clinical data on our proprietary hfCas12 #RNA editor and hfCas12Max #DNA editor, demonstrating their potential in treating diseases like #maculardegeneration , MECP2 duplication syndrome #DupMECP2 , #Alzheimers , #ALS , and #DMD . We’ll also highlight the enhanced editing efficiency of our HG-PRECISE platform (such as #hfCas12Max presented by Synthego Corporation ) and engineering AAV vectors, emphasizing our progress in developing next-generation genome medicines. #ESGCT #muscle #musculardystrophy #blindness #AMD #genetherapy #CNS #biotechnology #innovation #pharmaceutical #medicine #science

Transplant Diagnostics Market worth $6.8 billion by 2028 Download PDF Brochure:-https://lnkd.in/dEGyQf27 The size of global transplant diagnostics market in terms of revenue was estimated to be worth $4.4 billion in 2022 and is poised to reach $6.8 billion by 2028, growing at a CAGR of 7.4% from 2022 to 2028. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 bioMérieux Becton, Dickinson and Company  Thermo Fisher Scientific  Bio-Rad Laboratories, 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 GenDx One Lambda | A Thermo Fisher Scientific Brand, Horizon Discovery NantHealth Eurofins Transplant Genomics, Labcorp Clinical Genomics Inc. Olink Proteomics Illumina. Cypress Diagnostics Tissue Typing Precision Biologics, Inc. Astellas Pharma Haplogen Celerion ImmunoGen, Inc. Cerus Myriad Genetics PathGroup Medpace Genomatix Software GmbH Progenika Biopharma, S.A. Episurf Medical AB Fujirebio Diagnostics, Inc. Quest Diagnostics Proteome Sciences plc GENOOX Ambry Genetics Xenomics, Neurogene Inc. Luminex Asuragen, a Bio-Techne brand, Genospace PathAI Diagnostics PharmaMar Axovant Gene Therapies #transplantdiagnostics #organtransplant #hlatyping #genomics #immunology

Watch this summary of my poster presentation from #DD24 to find out more about our Cyto-Mine® for single-cell analysis and dispensing in CLD and Ab Discovery. Here we also showcase it's next iteration, Cyto-Mine® Chroma, and some of our upcoming assays!

Global preclinical CRO market to reach $11.3 billion by 2030 - This is already beating forecasts set a few years ago. A repost from yesterday here: https://lnkd.in/evhxj2Fd 📈 Increasing demand for specialised testing Growth in digital medicine strategies and gene therapies are some areas driving the need for specialised preclinical testing in silico services, with the market forecasted to grow at a 7% CAGR. #PreclinicalResearch #DrugDevelopment 🤝 Rising outsourcing in pharma Pharmaceutical/Biotech companies are increasingly relying on CROs for cost-effective preclinical studies, streamlining their focus on core R&D #PharmaOutsourcing #CROs ✔️ Tech advancements shaping the industry Adoption of 3D cell cultures and in silico models by CROs is seen as alternatives for preclinical research and reducing reliance on animal testing. #BiotechInnovation #PreclinicalTesting ✴️ These have positive implications for CRO's like IDL, but there is still increasing competition as we anticipate a tougher market to get into for newer ones. Sources: https://lnkd.in/ehFvduZ8 https://lnkd.in/eMTTeZE3 https://lnkd.in/eQvBMVbq

Does single-cell data increase probability of success in drug discovery and clinical phases? 🧐 Drug targets backed by single-cell data are x3 likely to reach phase III, when combined with genetic data 🎯 Read the pre-print of this brilliant study by Sanofi and Wellcome Sanger Institute here: https://lnkd.in/dwMYiBCx Human Cell Atlas project and single-cell omics promised to transform biology and medicine. This is proof for that promise: a demonstrated and quantified impact of single-cell target analysis on clinical success with clear examples & explanations 🙌 Congratulations to the team behind the study for tackling a research question many of us has been pondering over for years. A prominent example of industry x academic collaboration 💪 Emma Dann and Sarah Teichmann FMedSci FRS at Wellcome Sanger Institute, Erin Teeple, Virginia Savova, Ph. D. , Emanuele de Rinaldis and team at Sanofi, and Rasa Elmentaite at Ensocell. #DrugDiscovery #TargetDiscovery #SingleCellOmics #RnD

🌟Watch Jessica Hall, Senior Field Application Scientist, present our latest poster at Drug Discovery 2024, captured by Rizwan Chaudhrey. 🎥 Our poster highlights the power of Cyto-Mine® for single-cell analysis, selection, and isolation—ensuring monoclonality through advanced imaging. As Jessica explains: “Key in our cell line development is monoclonality assurance. Each picodroplet has 5 images taken to guarantee monoclonality is achieved.” 🔬 Key topics covered: ✅ The use of multiplexed assays to isolate valuable cells ✅ Increased efficiency in gene integration and clone selection ✅ High-throughput B cell screening for antibody discovery ✅ Cyto-Mine® Chroma: our next-gen platform launching in 2025, featured in the poster with its advanced multiplexing capabilities Find rare and valuable variants faster while reducing timelines by 2-3 months. Download the poster here: https://bit.ly/3A7850U #Biologics #Microfluidics #DrugDiscovery

Section IV.M.2.b.lxiv: Crispr Therapeutics Aktiengesellschaft (CRSP) CRISPR Therapeutics AG (CRSP) - Navigating Clinical Success and Market Expansion in 2024 Abstract CRISPR Therapeutics AG (CRSP) has emerged as a key player in the biotechnology sector, marked by significant clinical and financial developments in 2024. This analysis explores CRSP's recent strides in gene editing, focusing on the successful outcomes from the CTX112 Phase 1/2 trials for treating relapsed or refractory B-cell malignancies and the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation. The financial health of the company is scrutinized, highlighting the revenue from Casgevy post its approval in Switzerland and Canada, alongside the company's robust cash reserves. Strategic partnerships, particularly with Vertex Pharmaceuticals, are evaluated to understand their impact on CRSP's market position. Analyst sentiments, recent investment activities, and the competitive landscape are discussed to provide a holistic view of CRSP's standing in the gene therapy market. Ethical considerations and future pipeline developments are also addressed, offering insights into CRSP's potential trajectory in both therapeutic innovation and market expansion. #biotechnology, #biotech, #genetics, #geneediting, #crispr, #molecularbiology, #biochemistry, #syntheticbiology, #pharmacology, #stemcells, #genetherapy, #immunology, #microbiology, #biomedicalresearch, #biomanufacturing, #regenerativemedicine, #drugdiscovery, #biotechstartup, #bioinformatics, #clinicaltrials https://lnkd.in/euH_zHHe

𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐰𝐢𝐭𝐡 𝐑𝐍𝐀-𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐒𝐦𝐚𝐥𝐥 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭: https://lnkd.in/dHeF96u7 (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) As we stand at the forefront of #biopharmaceutical innovation, RNA-targeted small molecules are emerging as powerful tools in the fight against various diseases. By precisely targeting #RNA #structures, these compounds can modulate gene expression, offering new avenues for #treatment in areas previously deemed untouchable by conventional therapies. 🔬 𝐖𝐡𝐲 𝐑𝐍𝐀-𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐒𝐦𝐚𝐥𝐥 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬? ✔ 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: Tailored approaches to individual genetic profiles. ✔ 𝐃𝐢𝐯𝐞𝐫𝐬𝐞 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Potential to address cancer, genetic disorders, and infectious diseases. ✔ 𝐑𝐚𝐩𝐢𝐝 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Advancements in technology accelerate the discovery process. The promise of these molecules is not just theoretical. With ongoing research and #clinicaltrials, we are witnessing the dawn of a new era in drug development. 📌𝐒𝐨𝐮𝐫𝐜𝐞: @QuantumQuest_R1 📌𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫- I don't intend any copyright (DM me for credit & removal) #RNA #Biopharma #Innovation #PrecisionMedicine #DrugDevelopment #SmallMolecules #RNA #SmallMolecules #Biopharmaceuticals #PrecisionMedicine #DrugDiscovery #TargetedTherapy #GeneTherapy #InnovativeMedicine #RNAResearch #MolecularBiology